Merkel, C.
Whicher, C. H.
Bomanji, J.
Herrmann, K.
Ćwikła, J.
Jervis, N.
Wait, S.
Chiti, A.
Article History
First Online: 13 March 2020
Compliance with ethical standards
:
: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CM, CW and SW are employees of The Health Policy Partnership, which has received funding from Advanced Accelerator Applications, a Novartis Company, and from and Curium to coordinate this work on behalf of the independent and unpaid co-authors, in addition to a research report, report summary, animation and microsite on the topic of radioligand therapy. NJ has received Nurse Education Programme Organising Committee Honoraria from Ipsen UK. NJ is an employee of Neuroendocrine Cancer UK, which receives project grants and honoraria for advisory boards and speaking engagements from Ipsen, Novartis, ITM and MERCK. KH reports personal fees from Bayer, other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from Ipsen, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, outside the submitted work. AC reports speaker’s honoraria from AAA, General Electric; travel grants from General Electric, SIRTEX; advisory board honoraria from Blue Earth Diagnostics, AAA; unconditional scientific support from Sanofi Genzyme; all outside the submitted work.
: Not applicable.
: Institutional Review Board approval does not apply because the paper is an Editorial.
: Not applicable.
: Not applicable.